Xigen's PhII Success In Ocular Inflammation Opens Doors
Executive Summary
Xigen's innovative JNK inhibitor, brimapitide, the first peptide to be delivered subconjunctivally for post-surgical ocular inflammation, has met its primary endpoint in a Phase II study – a vital goal in the Swiss firm's long-term plan for the product.